Table 3.

ACR/EULAR remission rates and components at the last evaluable timepoint in the efficacy population. Remission is achieved if the patient has no more than 1 tender joint, no more than 1 swollen joint, CRP no greater than 1 mg/dl, and Patient Global Assessment of Disease Activity score no greater than 1. Last evaluable timepoint is the last week with ≥ 10% of patients originally included in each group at baseline. Last observation carried forward was used for TJC and SJC. Nonresponder imputation was used for missing CRP and Patient Global Assessment Disease Activity score.

Criterion, n (%)NE/NF MTX, n = 618DMARD-IR n = 2904TNF-IR, n = 464
Last evaluable timepointWeek 216Week 240Week 216
No. patients with efficacy assessment at timepoint7930386
TJC ≤ 139 (49.4)170 (56.1)30 (34.9)
SJC ≤ 156 (70.9)188 (62.0)39 (45.3)
CRP ≤ 1 mg/dl44 (55.7)200 (66.0)60 (69.8)
Patient global assessment of disease activity score ≤ 1 (1–10 scale)18 (22.8)58 (19.1)14 (16.3)
Remission (all ≤ 1)15 (19.0)45 (14.9)7 (8.1)
Remission (SDAI ≤ 3.3)16 (20.3)63 (20.8)10 (11.6)
  • ACR: American College of Rheumatology; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic drug; EULAR: European League Against Rheumatism; IR: inadequate response; MTX: methotrexate; NE/NF: never exposed/never failed; SDAI: Simplified Disease Activity Index; SJC: swollen joint count; TJC: tender joint count; TNF: tumor necrosis factor.